Lipid metabolism transcriptomics of murine microglia in Alzheimer's disease and neuroinflammation

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid-& beta; (A & beta;) plaques followed by intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. An unrestrained immune response by microglia, the resident cells of the central nervous system (CNS), leads to neuroinflammation which can amplify AD pathology. AD pathology is also driven by metabolic dysfunction with strong correlations between dementia and metabolic disorders such as diabetes, hypercholesterolemia, and hypertriglyceridemia. Since elevated cholesterol and triglyceride levels appear to be a major risk factor for developing AD, we investigated the lipid metabolism transcriptome in an AD versus non-AD state using RNA-sequencing (RNA-seq) and microarray datasets from N9 cells and murine microglia. We identified 52 differentially expressed genes (DEG) linked to lipid metabolism in LPS-stimulated N9 microglia versus unstimulated control cells using RNA-seq, 86 lipid metabolism DEG in 5XFAD versus wild-type mice by microarray, with 16 DEG common between both datasets. Functional enrichment and network analyses identified several biological processes and molecular functions, such as cholesterol homeostasis, insulin signaling, and triglyceride metabolism. Furthermore, therapeutic drugs targeting lipid metabolism DEG found in our study were identified. Focusing on drugs that target genes associated with lipid metabolism and neuroinflammation could provide new targets for AD drug development.

Automated summary

This study investigates the lipid metabolism transcriptome in Alzheimer's disease (AD) by analyzing RNA-sequencing and microarray datasets. The study identifies differentially expressed genes related to lipid metabolism and reveals their association with biological processes and molecular functions such as cholesterol homeostasis, insulin signaling, and triglyceride metabolism.